Therapeutic area intelligence for Drug Interaction with 1 indexed intelligence signal across regulatory, clinical, competitive, and market developments.

Signals: 1
Catalysts: 0
Companies: 1

Companies

AstraZeneca →

Assets

AZD5004 →

Recent signals(1)

ClinicalJuly 17, 2026

AstraZeneca's AZD5004 Study Evaluates Drug Interaction with Mitiglinide and Pioglitazone

AstraZeneca is conducting a study to assess the pharmacokinetics of mitiglinide and pioglitazone when administered with AZD5004.

Upcoming catalysts

No catalysts indexed for this entity yet.

Indications

Diabetes →

Newsletter

Get signals before the market moves

Concise strategic intelligence on regulatory, clinical, competitive, and market developments — free to subscribe.

No paywall. No spam. Unsubscribe anytime.